{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T17:13:18Z","timestamp":1772212398810,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,11,20]],"date-time":"2013-11-20T00:00:00Z","timestamp":1384905600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Cardiol"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s00246-013-0840-z","type":"journal-article","created":{"date-parts":[[2013,11,19]],"date-time":"2013-11-19T10:45:06Z","timestamp":1384857906000},"page":"699-704","source":"Crossref","is-referenced-by-count":29,"title":["Comparison of the Therapeutic and Side Effects of Tadalafil and Sildenafil in Children and Adolescents with Pulmonary Arterial Hypertension"],"prefix":"10.1007","volume":"35","author":[{"given":"Mohammad Reza","family":"Sabri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elham","family":"Beheshtian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,11,20]]},"reference":[{"key":"840_CR1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ijcard.2005.08.051","volume":"108","author":"F Affuso","year":"2006","unstructured":"Affuso F, Palmieri EA, Di Conza P et al (2006) Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension. Int J Cardiol 108:429\u2013431","journal-title":"Int J Cardiol"},{"key":"840_CR2","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.clinthera.2011.06.008","volume":"33","author":"SA Arif","year":"2011","unstructured":"Arif SA, Poon H (2011) Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension. Clin Ther 33:993\u20131004","journal-title":"Clin Ther"},{"key":"840_CR3","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.jacc.2009.04.011","volume":"54","author":"DB Badesch","year":"2009","unstructured":"Badesch DB, Champion HC, Gomez Sanchez MA et al (2009) Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 54:S55\u2013S66","journal-title":"J Am Coll Cardiol"},{"key":"840_CR4","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/j.jacc.2004.02.032","volume":"43","author":"RJ Barst","year":"2004","unstructured":"Barst RJ, McGoon M, Torbicki A et al (2004) Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 43:S40\u2013S47","journal-title":"J Am Coll Cardiol"},{"issue":"118","key":"840_CR5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1183\/09059180.00008410","volume":"19","author":"RMF Berger","year":"2010","unstructured":"Berger RMF, Bonnet D (2010) Treatment options for paediatric pulmonary arterial hypertension. Eur Respir Rev 19(118):321\u2013330","journal-title":"Eur Respir Rev"},{"issue":"5","key":"840_CR6","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/humupd\/4.5.565","volume":"4","author":"IT Cameron","year":"1998","unstructured":"Cameron IT, Campbell S (1998) Nitric oxide in the endometrium. Hum Reprod Update 4(5):565\u2013569","journal-title":"Hum Reprod Update"},{"key":"840_CR7","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/humrep\/15.suppl_3.96","volume":"15","author":"K Chwalisz","year":"2000","unstructured":"Chwalisz K, Garfield RE (2000) Role of nitric oxide in implantation and menstruation. Hum Reprod 15:96\u2013111","journal-title":"Hum Reprod"},{"issue":"49","key":"840_CR8","first-page":"A3901","volume":"155","author":"JM Douwes","year":"2011","unstructured":"Douwes JM, van Loon RL, Roothooft MT, Berger RM (2011) Pulmonary arterial hypertension in childhood. Ned Tijdschr Geneeskd 155(49):A3901","journal-title":"Ned Tijdschr Geneeskd"},{"key":"840_CR9","unstructured":"European Medicines Agency. http:\/\/www.ema.europa.eu"},{"key":"840_CR10","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.acvd.2009.12.001","volume":"103","author":"A Fraissea","year":"2010","unstructured":"Fraissea A, Jais X, Schleich J-M et al (2010) Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France. Arch Cardiovasc Dis 103:66\u201374","journal-title":"Arch Cardiovasc Dis"},{"key":"840_CR11","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1093\/eurheartj\/ehq152","volume":"31","author":"N Gali\u00e8","year":"2010","unstructured":"Gali\u00e8 N, Palazzini M, Manes A (2010) Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J 31:2080\u20132086","journal-title":"Eur Heart J"},{"key":"840_CR12","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ijcard.2006.10.017","volume":"120","author":"N Garg","year":"2007","unstructured":"Garg N, Sharma MK, Sinha N (2007) Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship. Int J Cardiol 120:306\u2013313","journal-title":"Int J Cardiol"},{"key":"840_CR13","first-page":"509","volume":"5","author":"A Hawkins","year":"2009","unstructured":"Hawkins A, Tulloh R (2009) Treatment of pediatric pulmonary hypertension. Vasc Health Risk Manag 5:509\u2013524","journal-title":"Vasc Health Risk Manag"},{"issue":"2","key":"840_CR14","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1358\/dot.2011.47.2.1544337","volume":"47","author":"YD Levin","year":"2011","unstructured":"Levin YD, White RJ (2011) Novel therapeutic approaches in pulmonary arterial hypertension: focus on tadalafil. Drugs Today (Barc) 47(2):145\u2013156","journal-title":"Drugs Today (Barc)"},{"key":"840_CR15","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.prrv.2010.07.002","volume":"11","author":"MT Roofthooft","year":"2010","unstructured":"Roofthooft MT, van Loon RL, Berger RM (2010) Management of pulmonary arterial hypertension in children. Paediatr Respir Rev 11:240\u2013245","journal-title":"Paediatr Respir Rev"},{"issue":"1","key":"840_CR16","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jacc.2009.04.012","volume":"54","author":"G Simonneau","year":"2009","unstructured":"Simonneau G, Robbins IM, Beghetti M et al (2009) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54(1):S43\u2013S54","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"840_CR17","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00246-012-0180-4","volume":"33","author":"S Takatsuki","year":"2012","unstructured":"Takatsuki S, Calderbank M, Dunbar Ivy D (2012) Initial experience with tadalafil in pediatric pulmonary arterial hypertension. Pediatr Cardiol 33(5):683\u2013688","journal-title":"Pediatr Cardiol"},{"key":"840_CR18","unstructured":"US Department of Health and Human Services, US Food and Drugs Administration (2012) FDA drug safety communication: FDA recommends against use of Revatio (sildenafil) in children with pulmonary hypertension. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm317123.htm"},{"key":"840_CR19","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jpeds.2009.02.036","volume":"155","author":"RL Loon van","year":"2009","unstructured":"van Loon RL, Roofthooft MT, van Osch-Gevers M et al (2009) Clinical characterization of pediatric pulmonary hypertension: complex presentation and diagnosis. J Pediatr 155:176\u2013182","journal-title":"J Pediatr"},{"key":"840_CR20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.amjcard.2010.02.023","volume":"106","author":"RL Loon van","year":"2010","unstructured":"van Loon RL, Roofthooft MT, Delhaas T et al (2010) Outcome of pediatric patients with pulmonary arterial hypertension in the era of new medical therapies. Am J Cardiol 106:117\u2013124","journal-title":"Am J Cardiol"},{"issue":"3","key":"840_CR21","first-page":"236","volume":"14","author":"YP Yu","year":"2012","unstructured":"Yu YP, Huang XM (2012) Progress in pharmacotherapy of pulmonary arterial hypertension in children. Zhongguo Dang Dai Er Ke Za Zhi 14(3):236\u2013240","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"issue":"2","key":"840_CR22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.21693\/1933-088X-10.2.109","volume":"10","author":"D Yung","year":"2011","unstructured":"Yung D (2011) An update on therapies for pediatric pulmonary arterial hypertension. Adv Pulm Hypertens 10(2):9\u2013114","journal-title":"Adv Pulm Hypertens"}],"container-title":["Pediatric Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00246-013-0840-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00246-013-0840-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00246-013-0840-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T14:53:38Z","timestamp":1564757618000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00246-013-0840-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,20]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["840"],"URL":"https:\/\/doi.org\/10.1007\/s00246-013-0840-z","relation":{},"ISSN":["0172-0643","1432-1971"],"issn-type":[{"value":"0172-0643","type":"print"},{"value":"1432-1971","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,20]]}}}